Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-120 (Ifenprodil) in Idiopathic Pulmonary Fibrosis and Associated Cough
NCT04318704Phase 2Completed
- Sponsor
- Algernon Pharmaceuticals Inc.
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ifenprodil in idiopathic pulmonary fibrosis (IPF) and cough, sponsored by Algernon Pharmaceuticals Inc. Primary endpoints: Reduction in the average number of coughs per hour over 24 hours at 12 weeks and Force Vital Capacity at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
ifenprodil
03
Conditions
idiopathic pulmonary fibrosis (IPF)cough
Beyond the preview
Go deeper on NCT04318704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318704.